Latest FDA-approved drug nirsevimab-alip (Beyfortus): A gamechanger for treatment of respiratory syncytial virus

J Med Virol. 2023 Oct;95(10):e29169. doi: 10.1002/jmv.29169.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Humans
  • Respiratory Syncytial Virus Infections* / drug therapy
  • Respiratory Syncytial Virus, Human*

Substances

  • nirsevimab
  • Antibodies, Monoclonal, Humanized